Key facts
- This page summarizes James E. Flynn's Form 4 filing for BiomX Inc. (PHGE).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 18 Apr 2025, 17:28.
James E. Flynn - 14 Apr 2025 Form 4 Insider Report for BiomX Inc. (PHGE)
- Reporting relationship
- Director, *Director by Deputization
- Issuer ticker
- PHGE
- Reported as of
- 14 Apr 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 18 Apr 2025, 17:28:34 UTC
- Prior SEC filing
- 03 Mar 2025
- Next SEC filing
- 23 Apr 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jonathan Isler, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
James E. Flynn filed Form 4 for BiomX Inc. (PHGE) on 18 Apr 2025.
Change
- Previous filing in this sequence was filed on 03 Mar 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PHGE
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +17,600
- Change %
- Price
- $0.000000
- Shares after
- 17,600
- Date
- 14 Apr 2025
- Ownership
- Through Deerfield Management Company, L.P.
- Underlying class
- Common Stock
- Underlying amount
- 17,600
- Exercise price
- $0.5380
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Jonathan S. Leff, a partner in Deerfield Management Company, L.P., serves as a director of the Issuer. The option granted to Jonathan S. Leff and reported herein is held for the benefit, and at the direction, of Deerfield Management Company, L.P. ("Deerfield Management").
Footnote F2
The options vest and become exercisable over four years, with 25% of the shares of common stock subject to the option vesting on April 14, 2026, and the reminder vesting in 12 equal quarterly installments over three years.
Footnote F3
This Form 4 is being filed by the undersigned as well as the entity listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). James E. Flynn is the sole member of the general partner of Deerfield Management Company, L.P. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
SEC remarks
Jonathan S. Leff, a partner in Deerfield Management, serves as a director of the Issuer. Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 3 with regard to BiomX Inc. filed with the Securities and Exchange Commission on March 19, 2024 by Deerfield Private Design Fund V, L.P., Deerfield Healthcare Innovations Fund II, L.P., Deerfield Mgmt V, L.P., Deerfield Mgmt HIF II, L.P., Deerfield Management Company, L.P. and James E. Flynn.